Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

NCT04695925 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

NCT04391283 ·Status: UNKNOWN

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728 ·Status: RECRUITING ·Phase: PHASE2

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857 ·Status: RECRUITING

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

NCT06970639 ·Status: RECRUITING ·Phase: PHASE3

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

NCT06319950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

NCT05011487 ·Status: RECRUITING ·Phase: PHASE2

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

NCT05513664 ·Status: UNKNOWN

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936 ·Status: SUSPENDED

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

NCT06735391 ·Status: RECRUITING ·Phase: PHASE3

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 ·Status: RECRUITING ·Phase: PHASE3

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

NCT05785208 ·Status: RECRUITING ·Phase: PHASE4

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 ·Status: COMPLETED

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2